TLSA
Tiziana Life Sciences Ltd
NASDAQ · Healthcare · Biotechnology · GB
$1.02
+4.67%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 421.0K | — | — | — | — |
| Gross Profit | (421.0K) | — | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 18.1M | 10.3M | 5.2M | 10.3M | 15.9M |
| SG&A Expense | 24.9M | — | 10.3M | 8.3M | 4.8M |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | 10.9M | 10.6M | 12.5M | 2.0M |
| Total Operating Expenses | 42.9M | 21.1M | 15.8M | 22.7M | 17.9M |
| Cost and Expenses | 43.4M | 21.1M | 15.8M | 22.7M | 17.9M |
| Operating Income (EBIT) | (43.4M) | (21.1M) | (15.8M) | (22.7M) | (17.9M) |
| Non-Operating | |||||
| Interest Income | 945.0K | 19.0K | 814.0K | 1.5M | — |
| Interest Expense | 24.0K | 18.0K | 6.0K | 12.6K | 8.6K |
| Net Interest Income | 921.0K | 1.0K | 808.0K | 1.4M | (8.6K) |
| Other Non-Op Income/Expense | 206.0K | 2.7M | (952.0K) | 937.9K | (996.8K) |
| Non-Operating Income (excl Interest) | (683.0K) | (2.7M) | 946.0K | (950.5K) | 988.2K |
| EBT (Pre-Tax Income) | (43.2M) | (18.4M) | (16.7M) | (21.8M) | (18.9M) |
| Income Tax Expense | (8.2M) | — | (4.9M) | 567.5K | — |
| Bottom Line | |||||
| Net Income | (34.9M) | (18.4M) | (11.9M) | (22.4M) | (18.9M) |
| Earnings from Cont. Ops | (34.9M) | (18.4M) | (11.9M) | (22.4M) | (18.9M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (34.9M) | (18.4M) | (11.9M) | (22.4M) | (18.9M) |
| Per Share | |||||
| Basic EPS | ($0.63) | ($0.32) | ($0.22) | ($0.42) | ($0.36) |
| Diluted EPS | ($0.63) | ($0.32) | ($0.22) | ($0.42) | ($0.36) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 59.5M | 59.1M | 53.3M | 50.8M | 50.8M |
| Diluted Shares Outstanding | 59.5M | 59.1M | 53.3M | 50.8M | 50.8M |
| Profitability Metrics | |||||
| EBITDA | (42.3M) | (18.2M) | (16.6M) | (21.7M) | (18.9M) |
| D&A | 421.0K | 234.0K | 124.0K | 121.3K | 62.7K |
| EBIT | (42.7M) | (18.4M) | (16.7M) | (21.8M) | (18.9M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Dec 1, 2025